The Bureau International des Expositions (BIE) announces the official list of candidates for Specialised Expo 2022/23: Poland (Łódź), United States (Minneapolis), Brazil (Rio de Janeiro) and Argentina (Buenos Aires)
The Bureau International des Expositions (BIE) has closed the candidature period for Specialised Expo 2022/23. Four countries have submitted competing bids to organise Specialised Expo 2022/23: the Republic of Poland, the United States of America, the Federative Republic of Brazil and the Republic of Argentina.
The 169 Member States of the BIE will elect the host country of Specialised Expo 2022/23 at the 162nd General Assembly in November 2017.
Poland’s bid is for a Specialised Expo in the city of Łódź between 15 June and 15 September 2022 under the theme “City Re:Invented.”
The United States’ bid is for a Specialised Expo in Minneapolis between 15 May and 15 August 2023 under the theme “Wellness and Well Being for All: Healthy People, Healthy Planet.” The United States is not a Member State of the BIE.*
Brazil’s bid is for a Specialised Expo in Rio de Janeiro between 4 March and 27 May 2022 under the theme “Metropolitan Cities and Sustainability: Cross Border Potentials.”
Argentina’s bid is for a Specialised Expo in Buenos Aires between 15 January and 15 April 2023 under the theme “Science, Innovation, Art and Creativity for the Human Development.”
The Secretary General of the BIE, Vicente G. Loscertales, stated that “these four candidatures demonstrate a high level of interest for this type of Expo.” The project examination phase for Specialised Expo 2022/23 will take place over the next few months. Each candidate will submit a bid dossier, to be followed by a BIE Enquiry Mission. The projects will then be presented to the General Assembly of the BIE on 14 June 2017. The election of the host country by the 169 Member States of the BIE will take place at the subsequent General Assembly in November 2017.
Specialised Expos, known officially as International Recognised Exhibitions, can be organised in the interval between two World Expos. They can last up to three months and are designed to respond to a precise challenge facing humanity. The most recent Specialised Expo was held in the city of Yeosu in the Republic of Korea in 2012, which attracted over 8 million visitors under the theme “The Living Ocean and Coast”. The next Specialised Expo is to take place in Astana, the capital of Kazakhstan, between 10 June and 10 September 2017 under the theme “Future Energy”.
* In accordance with BIE regulations, Member States must be given priority over non-Member States.
The Bureau International des Expositions (BIE) is the intergovernmental organisation embodying the commitment of its 169 member States to lead, promote and foster International Exhibitions for the benefit of the citizens of the international community.
The BIE oversees four types of International Exhibitions: World Expos (International Registered Exhibitions), Specialised Expos (International Recognised Exhibitions), Horticultural Expos and the Triennale di Milano.
International Exhibitions are global events dedicated to finding solutions to specific challenges facing humanity by offering a journey inside the Expo theme through engaging and immersive activities.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and